Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 7,632 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 15 more

Conditions: Chemotherapy Induced Nausea and Vomiting
Interventions: granisetron transdermal system, Granisetron IV; Drug
Lead sponsor: Kyowa Kirin Pharmaceutical Development Ltd; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 8 more

Conditions: Neoplasms
Interventions: GSK3901961, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 21 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 42 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Welchol, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 107
States / cities: Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 87 more

Conditions: Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Gliosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Rhabdomyosarcoma
Interventions: Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 74
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more

Conditions: Hemostasis
Interventions: Human thrombin, Bovine thrombin; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Pasadena, California + 17 more

Conditions: Psoriasis
Interventions: Alefacept exposure; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,897 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Gadsden, Alabama + 206 more

Conditions: Obese, Healthy, Bariatric Surgery Candidate
Interventions: Endoscopic biopsy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Erectile Dysfunction
Interventions: placebo, avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 33 more

Conditions: Intermittent Claudication
Interventions: K-134, Cilostazol 100 mg BID, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: clarithromycin, prasterone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Advanced Lung Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Best Practice, Educational Intervention, Health Promotion and Education, Questionnaire Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Tempus AI; Industry
Eligibility: Not listed
Enrollment: 77 participants
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Fountain Valley, California • Jacksonville, Florida • Honolulu, Hawaii + 7 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jacksonville, Florida

Conditions: Chordoma
Interventions: BN-Brachyury plus radiation; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Obesity, Overweight, Osteoarthritis, Knee
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Escondido, California • Lancaster, California • Palm Springs, California + 14 more

Conditions: Astigmatism
Interventions: enfilcon A, senofilcon A; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years to 38 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Jacksonville, Florida • Lafayette, Louisiana

Conditions: Breast Cancer
Interventions: Palbociclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 5,796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 192
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more

Conditions: Persistent Corneal Epithelial Defect
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more

Conditions: Visual Acuity
Interventions: JJVC Investigational Multifocal Contact Lens (senofilcon A c3), Dailies Total 1® Multifocal Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Maitland, Florida • Pittsburg, Florida + 3 more

Conditions: Pressure Ulcer
Interventions: Adipose-derived stromal cells, Adipose-derived stromal cells; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Welchol as Monotherapy for Type 2 Diabetes Mellitus

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

Assessment and Tracking of Long-term Alefacept Safety

Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome

Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED

Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Umbrella Study for Analysis of Data Related to Patients With Cancer

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

CARE: Cancer Risk Perception and Women of Color

BN Brachyury and Radiation in Chordoma

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses

PALbociclib CoLlaborative Adjuvant Study

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population

Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers